Biohaven (BHVN) said Monday that it is "positioned to achieve significant milestones" in 2026 as it provided updates on several of its clinical programs.

Regarding its IgA nephropathy program, the company said it completed a meeting with the US Food and Drug Administration in Q4 2025 to align its study design and expects to begin the trial in early 2026.

The company said that it is planning a study evaluating BHV-1300 in Graves' disease, an autoimmune condition, this year.

Biohaven announced preliminary data in a study evaluating opakalim in an ongoing open-label extension study in focal epilepsy, and said pivotal results from the trial are expected this year.

Regarding its obesity study, the company said it began dosing patients in a phase 2 trial with its myostatin-activin inhibitor for weight loss in Q4 2025, with topline results expected this year.

The company also provided updates on its studies related to cancer, Parkinson's disease, and others.

Biohaven shares were up 10% in recent Monday trading.

Price: 11.47, Change: +0.36, Percent Change: +3.21